Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.
A HurrellA Beardmore-GrayK DuhigL WebsterLucy C ChappellA H ShennanPublished in: BJOG : an international journal of obstetrics and gynaecology (2020)
Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing.
Keyphrases
- growth factor
- tyrosine kinase
- healthcare
- primary care
- epidermal growth factor receptor
- pregnancy outcomes
- clinical practice
- quality improvement
- birth weight
- gestational age
- preterm birth
- pregnant women
- public health
- polycystic ovary syndrome
- emergency department
- pulmonary embolism
- type diabetes
- metabolic syndrome
- preterm infants
- electronic health record
- cervical cancer screening